Residency · Residency · Infectiousdisease

Hospital-Acquired and Ventilator-Associated Pneumonia

Definitions and Epidemiology

Key Definitions (ATS/IDSA 2016)

Hospital-acquired pneumonia is defined as pneumonia developing 48 hours or more after hospital admission in a patient who was not intubated at the time of diagnosis. Ventilator-associated pneumonia is defined as pneumonia developing 48 hours or more after endotracheal intubation. Ventilator-associated tracheobronchitis represents an intermediate entity characterized by purulent secretions and a positive respiratory culture without a new radiographic infiltrate, and the treatment benefit for this condition remains debated. Importantly, the 2016 ATS/IDSA guidelines eliminated the category of healthcare-associated pneumonia (HCAP), which had been introduced in the 2005 guidelines. The HCAP designation was removed because it was associated with unnecessary broad-spectrum antibiotic coverage in patients whose actual risk of multidrug-resistant organisms was often no higher than that of patients with community-acquired pneumonia.

Epidemiology

VAP affects 5 to 15 percent of mechanically ventilated patients, with an incidence of 2 to 16 episodes per 1,000 ventilator-days. HAP is less well-studied, with an estimated incidence of 3 to 5 per 1,000 hospital admissions. The attributable mortality of VAP is estimated at approximately 13 percent, though significant debate exists regarding the true attributable mortality versus VAP serving as a marker of disease severity. VAP prolongs ICU stay by 4 to 13 days and increases cost by 20,000 to 40,000 dollars per episode.

Microbiology

The microbiology of HAP and VAP is dominated by S. aureus (both MRSA and MSSA), Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Enterobacter species, and E. coli. Polymicrobial infection occurs in 20 to 40 percent of VAP cases. Early-onset VAP, occurring within the first five days of ventilation, more commonly involves community-type pathogens including MSSA, S. pneumoniae, H. influenzae, and susceptible gram-negatives. Late-onset VAP, occurring at five days or more, carries a higher risk of MDR organisms including MRSA, Pseudomonas, Acinetobacter, and ESBL-producing Enterobacterales. The local antibiogram is critical for guiding empiric antibiotic selection, as institutional variation in resistance patterns is substantial.

Diagnosis

Clinical Suspicion

Clinical suspicion for HAP or VAP is raised by the development of a new or progressive radiographic infiltrate in combination with at least two of the following: fever above 38 degrees Celsius, leukocytosis above 10,000 or leukopenia below 4,000, and purulent secretions. The Clinical Pulmonary Infection Score is a composite scoring system incorporating temperature, white blood cell count, secretion characteristics, oxygenation, radiographic findings, and culture results, with a score of 6 or above being suggestive of pneumonia. However, the CPIS has poor sensitivity and specificity in clinical practice and is more useful as a research tool than as a bedside clinical decision aid. The differential diagnosis is broad and includes atelectasis, pulmonary edema, ARDS, pulmonary hemorrhage, and drug fever.

Diagnostic Approaches

The non-invasive approach utilizes endotracheal aspirate with a quantitative threshold of 10 to the sixth CFU per milliliter or semi-quantitative reporting of moderate to heavy growth. The invasive approach employs bronchoalveolar lavage with a threshold of 10 to the fourth CFU per milliliter or protected specimen brush with a threshold of 10 to the third. The 2016 ATS/IDSA guidelines recommend non-invasive sampling with semi-quantitative cultures as the preferred approach for most patients, based on the absence of a demonstrated mortality benefit for invasive sampling. Invasive sampling should be considered in the immunocompromised host where the differential diagnosis is broader, when the diagnosis is uncertain, or when the patient has failed to respond to empiric therapy. Blood cultures are positive in only 8 to 15 percent of VAP cases, and when positive, should prompt consideration of a metastatic source or concomitant bacteremia. Procalcitonin may assist in guiding treatment duration but is not sufficiently reliable to withhold antibiotics when clinical suspicion is high.

<image>A diagnostic comparison diagram showing invasive vs. non-invasive approaches to VAP diagnosis. Left panel "Non-Invasive (Recommended)" shows: endotracheal aspirate collection technique with quantitative threshold (≥10^6 CFU/mL) or semi-quantitative reporting (1+ to 4+). Right panel "Invasive" shows: BAL (threshold ≥10^4 CFU/mL) with illustration of bronchoscope in airway, and Protected Specimen Brush (threshold ≥10^3 CFU/mL) with brush emerging from sheath. Below each panel, list advantages and disadvantages. Include a "Clinical Bottom Line" box: "ATS/IDSA 2016 recommends non-invasive approach -- no mortality difference between strategies." Use a medical illustration style with airway anatomy cross-sections.</image>

Empiric Antibiotic Therapy

Risk Stratification for MDR Organisms

The ATS/IDSA 2016 guidelines identify several risk factors for MDR pathogens that should guide the breadth of empiric therapy. These include intravenous antibiotic use within the prior 90 days, septic shock at the time of VAP diagnosis, ARDS preceding VAP, five or more days of hospitalization prior to VAP onset, acute renal replacement therapy prior to VAP, prior isolation of an MDR organism from respiratory culture, and high institutional prevalence of resistant organisms defined as greater than 10 to 20 percent MRSA or greater than 10 percent MDR gram-negatives.

Empiric Regimens

For patients at low risk for MDR organisms and without MRSA risk factors, monotherapy with a single anti-pseudomonal beta-lactam is appropriate. Options include piperacillin-tazobactam 4.5 grams intravenously every 6 hours, cefepime 2 grams every 8 hours, meropenem 1 gram every 8 hours, or imipenem 500 milligrams every 6 hours. Dual gram-negative coverage and MRSA coverage are not needed in this setting.

For patients at high risk for MDR organisms or with structural risk factors, the regimen should include an anti-pseudomonal beta-lactam plus a second gram-negative agent from a different class, such as a fluoroquinolone, aminoglycoside, or aztreonam, plus an anti-MRSA agent if MRSA risk factors are present. Anti-MRSA options include vancomycin dosed to an AUC/MIC of 400 to 600 or linezolid 600 milligrams intravenously every 12 hours.

Key Antibiotic Considerations

Extended-infusion piperacillin-tazobactam over four hours improves pharmacokinetic and pharmacodynamic target attainment and should be considered particularly when the MIC is 16 or above. Cefepime should similarly be administered as an extended infusion over three to four hours, with monitoring for neurotoxicity, particularly non-convulsive status epilepticus in patients with renal impairment, when trough concentrations exceed 20 milligrams per liter. Meropenem may be given as a three-hour extended infusion, with continuous infusion supported by the BLING III trial. Inhaled aminoglycosides may serve as adjunctive therapy for MDR gram-negatives, though systemic aminoglycosides alone are inferior to beta-lactams for pneumonia treatment. Regarding the comparison between linezolid and vancomycin for MRSA pneumonia, linezolid achieves substantially higher epithelial lining fluid concentrations at 100 percent versus 20 to 50 percent for vancomycin, and meta-analyses suggest a trend toward better outcomes, though definitive superiority has not been established. The ZEPHyR trial demonstrated that linezolid met non-inferiority criteria and showed higher clinical cure rates, though methodologic concerns have limited the strength of this conclusion.

Duration of Therapy

7 Days is Standard

The 2016 ATS/IDSA guidelines recommend a seven-day course for most HAP and VAP, supported by multiple randomized controlled trials. The landmark PneumA trial by Chastre and colleagues in 2003 compared eight versus fifteen days of antibiotic therapy for VAP and demonstrated no difference in mortality, ICU length of stay, or ventilator-free days, with the notable exception of higher recurrence rates with the shorter course for non-fermenting gram-negatives, specifically Pseudomonas and Acinetobacter, at 40 percent versus 25 percent. Consequently, for Pseudomonas or Acinetobacter VAP, a fourteen-day course should be considered given the higher relapse risk with shorter therapy. Procalcitonin-guided discontinuation, with stopping criteria of PCT below 0.5 or greater than 80 percent decline from peak, safely reduces duration by two to three days as demonstrated in the PRORATA and SAPS trials.

De-escalation and Antibiotic Optimization

48-72 Hour Reassessment

Reassessment of the antibiotic regimen at 48 to 72 hours when culture and susceptibility data become available is essential for antibiotic optimization. De-escalation should target the narrowest effective agent, for example transitioning from vancomycin plus meropenem plus tobramycin to cefepime alone for a susceptible Pseudomonas isolate. MRSA coverage should be discontinued if respiratory cultures are negative for MRSA at 48 to 72 hours, and the second gram-negative agent should be stopped if susceptibilities confirm that single-agent coverage is adequate. If all cultures return negative and the patient is clinically improving, strong consideration should be given to stopping antibiotics altogether, as the patient may not have had pneumonia.

<image>A timeline infographic showing the optimal management of VAP from day 0 to day 7+. Day 0: "Clinical suspicion + respiratory cultures obtained + empiric broad-spectrum antibiotics started." Day 1-2: "Monitor clinical response, await culture data." Day 2-3: "DECISION POINT - Culture results available" with two branches: "Positive cultures: de-escalate to narrowest effective agent based on susceptibilities" and "Negative cultures + improving: consider stopping antibiotics." Day 3-5: "Clinical reassessment - improving?" with "Yes: continue targeted therapy" and "No: broaden coverage, repeat cultures, consider alternative diagnosis." Day 7: "Standard stop date for most VAP; extend to 14 days for Pseudomonas/Acinetobacter if not fully responding." Include a PCT curve overlay showing how serial procalcitonin guides duration. Use a horizontal timeline format with color-coded decision points.</image>

Prevention -- VAP Bundle

Evidence-Based Prevention Strategies

Elevation of the head of bed to 30 to 45 degrees reduces aspiration of gastric contents and is a cornerstone of VAP prevention. Daily sedation interruption combined with spontaneous breathing trials reduces the duration of mechanical ventilation. Chlorhexidine oral care at 0.12 percent concentration was previously a standard recommendation but has been removed from many institutional bundles following recent meta-analyses demonstrating a possible harm signal, specifically an association with increased mortality. Subglottic secretion drainage, utilizing a specialized endotracheal tube with a dorsal suction port, reduces VAP incidence by approximately 50 percent with a number needed to treat of approximately 10. Standard ICU preventive measures including venous thromboembolism prophylaxis and peptic ulcer prophylaxis contribute indirectly to VAP prevention. Avoidance of unnecessary intubation through the use of high-flow nasal cannula or non-invasive ventilation when appropriate, early mobilization, and proper ventilator circuit management, including avoidance of routine circuit changes and minimization of condensate accumulation, complete the bundle.

Controversies

Selective digestive decontamination and selective oropharyngeal decontamination have been proven in multiple European randomized controlled trials to reduce VAP incidence and mortality, but they are not widely adopted in the United States due to concerns about promoting resistance in settings endemic for MDR organisms. Probiotics for VAP prevention have insufficient evidence and are not routinely recommended.

HAP-Specific Considerations

Non-Ventilated HAP

Non-ventilated hospital-acquired pneumonia is less studied than VAP, though treatment principles are similar. Sputum cultures may be more difficult to obtain in non-intubated patients. Risk factors for MDR organisms parallel those identified for VAP, and empiric therapy mirrors the VAP approach stratified by MDR risk. The recommended duration is seven days, consistent with VAP guidelines. Intravenous-to-oral conversion is appropriate when the patient is clinically improving, tolerating oral intake, and the organism is susceptible to an available oral agent.

Key Clinical Pearls

• The term "HCAP" has been eliminated -- do not reflexively broaden empiric therapy for patients from nursing homes without specific MDR risk factors
• 7 days of antibiotic therapy is sufficient for most HAP/VAP; the exception is Pseudomonas/Acinetobacter where 14 days may reduce relapse
• Local antibiogram should drive empiric therapy decisions -- a unit-specific antibiogram is more informative than a hospital-wide antibiogram
• De-escalation at 48-72 hours is safe, reduces antibiotic exposure, and should be aggressively pursued
• If cultures are negative and the patient is improving, consider stopping antibiotics -- the patient may not have had pneumonia
• Linezolid achieves higher lung concentrations than vancomycin but definitive superiority for MRSA pneumonia has not been established
• Chlorhexidine oral care for VAP prevention is no longer universally recommended due to potential mortality signal

References

1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 ATS/IDSA clinical practice guidelines. Clin Infect Dis. 2016;63(5):e61-e111.
2. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults (PneumA). JAMA. 2003;290(19):2588-2598.
3. Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and non-ventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(6):687-713.
4. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia (ZEPHyR). Clin Infect Dis. 2012;54(5):621-629.
5. Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs intermittent beta-lactam antibiotic infusions in critically ill patients (BLING III). JAMA. 2022;328(18):1855-1865.

Read this lecture as Markdown